IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
IGC Pharma Adds Advisor in Artificial Intelligence
IGC Pharma Announces $3M Unregistered Private Placement of its Common Stock
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
IGC Pharma Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
IGC Pharma Reports Third Quarter Fiscal 2024 Results
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s